Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus capecitabine for advanced pancreatic cancer
NL-OMON31280Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and capecitabine in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Amsterdam University Medical Center. Primary endpoint: Six-month survival rate. Planned start Mar 2007; status: not yet recruiting.
02
Drugs
everolimuscapecitabine
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON31280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31280.